參考文獻 |
[1] M.A. Duggan, W.F. Anderson, S. Altekruse, L. Penberthy, M.E. Sherman, The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship, Am. J. Surg. Pathol., 40 (2016) e94–e102.
[2] P.M. de Groot, C.C. Wu, B.W. Carter, R.F. Munden, The epidemiology of lung cancer, Transl Lung Cancer Res, 7 (2018) 220–233.
[3] J.S. Chang, L.-T. Chen, Y.-S. Shan, S.-F. Lin, S.-Y. Hsiao, C.-R. Tsai, S.-J. Yu, H.-J. Tsai, Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan, Medicine , 94 (2015) e969.
[4] B.-Y. Wang, J.-Y. Huang, C.-Y. Cheng, C.-H. Lin, J.-L. Ko, Y.-P. Liaw, Lung cancer and prognosis in taiwan: a population-based cancer registry, J. Thorac. Oncol., 8 (2013) 1128–1135.
[5] N. Riggi, M. Aguet, I. Stamenkovic, Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment, Annu. Rev. Pathol., 13 (2018) 117–140.
[6] S. Valastyan, R.A. Weinberg, Tumor metastasis: molecular insights and evolving paradigms, Cell, 147 (2011) 275–292.
[7] Y.-N. Kim, K.H. Koo, J.Y. Sung, U.-J. Yun, H. Kim, Anoikis resistance: an essential prerequisite for tumor metastasis, Int. J. Cell Biol., 2012 (2012) 306879.
[8] M.L. Taddei, E. Giannoni, T. Fiaschi, P. Chiarugi, Anoikis: an emerging hallmark in health and diseases, J. Pathol., 226 (2012) 380–393.
[9] N.M. Fofaria, S.K. Srivastava, STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells, Carcinogenesis, 36 (2015) 142–150.
[10] P. Zhang, Y. Song, Y. Sun, X. Li, L. Chen, L. Yang, Y. Xing, AMPK/GSK3β/β-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming, FASEB J., (2018) fj201701078R.
[11] Y.-L. Tai, L.-C. Chen, T.-L. Shen, Emerging roles of focal adhesion kinase in cancer, Biomed Res. Int., 2015 (2015) 690690.
[12] S.M. Frisch, K. Vuori, E. Ruoslahti, P.Y. Chan-Hui, Control of adhesion-dependent cell survival by focal adhesion kinase, J. Cell Biol., 134 (1996) 793–799.
[13] E. Pachmayr, C. Treese, U. Stein, Underlying Mechanisms for Distant Metastasis - Molecular Biology, Visc Med, 33 (2017) 11–20.
[14] N.L. Collins, M.J. Reginato, J.K. Paulus, D.C. Sgroi, J. Labaer, J.S. Brugge, G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression, Mol. Cell. Biol., 25 (2005) 5282–5291.
[15] V.M. Golubovskaya, Focal adhesion kinase as a cancer therapy target, Anticancer Agents Med. Chem., 10 (2010) 735–741.
[16] M. Kohno, J. Pouyssegur, Targeting the ERK signaling pathway in cancer therapy, Ann. Med., 38 (2006) 200–211.
[17] M.E. Roh, M. Cosgrove, K. Gorski, I.S. Hitchcock, Off-targets effects underlie the inhibitory effect of FAK inhibitors on platelet activation: studies using Fak-deficient mice, J. Thromb. Haemost., 11 (2013) 1776–1778.
[18] M. Donovan, B. Olofsson, A.L. Gustafson, L. Dencker, U. Eriksson, The cellular retinoic acid binding proteins, J. Steroid Biochem. Mol. Biol., 53 (1995) 459–465.
[19] Y. Kainov, I. Favorskaya, V. Delektorskaya, G. Chemeris, A. Komelkov, A. Zhuravskaya, L. Trukhanova, E. Zueva, B. Tavitian, N. Dyakova, I. Zborovskaya, E. Tchevkina, CRABP1 provides high malignancy of transformed mesenchymal cells and contributes to the pathogenesis of mesenchymal and neuroendocrine tumors, Cell Cycle, 13 (2014) 1530–1539.
[20] R.-Z. Liu, E. Garcia, D.D. Glubrecht, H.Y. Poon, J.R. Mackey, R. Godbout, CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid, Mol. Cancer, 14 (2015) 129.
[21] S.-S. Han, W.J. Kim, Y. Hong, S.-H. Hong, S.-J. Lee, D.R. Ryu, W. Lee, Y.H. Cho, S. Lee, Y.-J. Ryu, J.Y. Won, H. Rhee, J.H. Park, S.J. Jang, J.S. Lee, C.-M. Choi, J.C. Lee, S.D. Lee, Y.-M. Oh, RNA sequencing identifies novel markers of non-small cell lung cancer, Lung Cancer, 84 (2014) 229–235.
[22] S.G. Codreanu, M.D. Hoeksema, R.J.C. Slebos, L.J. Zimmerman, S.M.J. Rahman, M. Li, S.-C. Chen, H. Chen, R. Eisenberg, D.C. Liebler, P.P. Massion, Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma, J. Proteome Res., 16 (2017) 3266–3276.
[23] Y. Zhang, H. Wang, J. Wang, L. Bao, L. Wang, J. Huo, X. Wang, Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer, Cancer Metastasis Rev., 34 (2015) 249–264.
[24] F. Bolognani, A.-I. Gallani, L. Sokol, D.S. Baskin, N. Meisner-Kober, mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells, J. Neurooncol., 106 (2012) 531–542.
[25] N.-C. Meisner, W. Filipowicz, Properties of the Regulatory RNA-Binding Protein HuR and its Role in Controlling miRNA Repression, Adv. Exp. Med. Biol., 700 (2011) 106–123.
[26] W. Yan, Y. Zhang, J. Zhang, S.-J. Cho, X. Chen, HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via ΔNp63, PLoS One, 7 (2012) e45336.
[27] J. Wang, Y. Guo, H. Chu, Y. Guan, J. Bi, B. Wang, Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis, Int. J. Mol. Sci., 14 (2013) 10015–10041.
[28] J. Wang, W. Zhao, Y. Guo, B. Zhang, Q. Xie, D. Xiang, J. Gao, B. Wang, Z. Chen, The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis, Oncology, 76 (2009) 420–429.
[29] R. Muralidharan, J. Panneerselvam, A. Chen, Y.D. Zhao, A. Munshi, R. Ramesh, HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer, Cancer Gene Ther., 22 (2015) 581–590.
[30] M. Heinonen, A. Hemmes, K. Salmenkivi, K. Abdelmohsen, S.-T. Vilén, M. Laakso, M. Leidenius, T. Salo, S. Hautaniemi, M. Gorospe, P. Heikkilä, C. Haglund, A. Ristimäki, Role of RNA binding protein HuR in ductal carcinoma in situ of the breast, J. Pathol., 224 (2011) 529–539.
[31] A.C. Vreeland, L. Levi, W. Zhang, D.C. Berry, N. Noy, Cellular retinoic acid-binding protein 2 inhibits tumor growth by two distinct mechanisms, J. Biol. Chem., 289 (2014) 34065–34073.
[32] A.C. Vreeland, S. Yu, L. Levi, D. de Barros Rossetto, N. Noy, Transcript stabilization by the RNA-binding protein HuR is regulated by cellular retinoic acid-binding protein 2, Mol. Cell. Biol., 34 (2014) 2135–2146.
[33] D.W. Laird, Life cycle of connexins in health and disease, Biochem. J, 394 (2006) 527–543.
[34] J.L. Esseltine, D.W. Laird, Next-Generation Connexin and Pannexin Cell Biology, Trends Cell Biol., (2016).
[35] S. Boitano, E.R. Dirksen, W.H. Evans, Sequence-specific antibodies to connexins block intercellular calcium signaling through gap junctions, Cell Calcium, 23 (1998) 1–9.
[36] M. Sanson, V. Marcaud, E. Robin, C. Valéry, F. Sturtz, B. Zalc, Connexin 43-mediated bystander effect in two rat glioma cell models, Cancer Gene Ther., 9 (2002) 149–155.
[37] A. Gupta, H. Anderson, A.M. Buo, M.C. Moorer, M. Ren, J.P. Stains, Communication of cAMP by connexin43 gap junctions regulates osteoblast signaling and gene expression, Cell. Signal., 28 (2016) 1048–1057.
[38] L. Garcia-Rodríguez, S. Pérez-Torras, M. Carrió, A. Cascante, I. García-Ribas, A. Mazo, C. Fillat, Connexin-26 is a key factor mediating gemcitabine bystander effect, Mol. Cancer Ther., 10 (2011) 505–517.
[39] H. Goodall, B. Maro, Major loss of junctional coupling during mitosis in early mouse embryos, J. Cell Biol., 102 (1986) 568–575.
[40] L.S. Stein, J. Boonstra, R.C. Burghardt, Reduced cell-cell communication between mitotic and nonmitotic coupled cells, Exp. Cell Res., 198 (1992) 1–7.
[41] M. Vinken, T. Vanhaecke, P. Papeleu, S. Snykers, T. Henkens, V. Rogiers, Connexins and their channels in cell growth and cell death, Cell. Signal., 18 (2006) 592–600.
[42] H.A. Coller, Is cancer a metabolic disease?, Am. J. Pathol., 184 (2014) 4–17.
[43] T. Aasen, M. Mesnil, C.C. Naus, P.D. Lampe, D.W. Laird, Gap junctions and cancer: communicating for 50 years, Nat. Rev. Cancer, 16 (2016) 775–788.
[44] D. Banerjee, Connexin’s Connection in Breast Cancer Growth and Progression, Int. J. Cell Biol., 2016 (2016) 9025905.
[45] S.L. Phillips, C.B. Williams, J.N. Zambrano, C.J. Williams, E.S. Yeh, Connexin 43 in the development and progression of breast cancer: What’s the connection? (Review), Int. J. Oncol., 51 (2017) 1005–1013.
[46] L. Kanczuga-Koda, S. Sulkowski, A. Lenczewski, M. Koda, A. Wincewicz, M. Baltaziak, M. Sulkowska, Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer, J. Clin. Pathol., 59 (2006) 429–433.
[47] B. Tang, Z.-H. Peng, P.-W. Yu, G. Yu, F. Qian, Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes, Med. Oncol., 28 (2011) 502–508.
[48] Y.W. Zhang, I. Morita, M. Ikeda, K.W. Ma, S. Murota, Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27, Oncogene, 20 (2001) 4138–4149.
[49] S. Sirnes, J. Bruun, M. Kolberg, A. Kjenseth, G.E. Lind, A. Svindland, A. Brech, A. Nesbakken, R.A. Lothe, E. Leithe, E. Rivedal, Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome, Int. J. Cancer, 131 (2012) 570–581.
[50] S.R. Polusani, E.A. Kalmykov, A. Chandrasekhar, S.N. Zucker, B.J. Nicholson, Cell coupling mediated by connexin 26 selectively contributes to reduced adhesivity and increased migration, J. Cell Sci., 129 (2016) 4399–4410.
[51] M.K. Elzarrad, A. Haroon, K. Willecke, R. Dobrowolski, M.N. Gillespie, A.-B. Al-Mehdi, Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium, BMC Med., 6 (2008) 20.
[52] K. Stoletov, J. Strnadel, E. Zardouzian, M. Momiyama, F.D. Park, J.A. Kelber, D.P. Pizzo, R. Hoffman, S.R. VandenBerg, R.L. Klemke, Role of connexins in metastatic breast cancer and melanoma brain colonization, J. Cell Sci., 126 (2013) 904–913.
[53] C. Lamiche, J. Clarhaut, P.-O. Strale, S. Crespin, N. Pedretti, F.-X. Bernard, C.C. Naus, V.C. Chen, L.J. Foster, N. Defamie, M. Mesnil, F. Debiais, L. Cronier, The gap junction protein Cx43 is involved in the bone-targeted metastatic behaviour of human prostate cancer cells, Clin. Exp. Metastasis, 29 (2012) 111–122.
[54] J.H.-C. Lin, T. Takano, M.L. Cotrina, G. Arcuino, J. Kang, S. Liu, Q. Gao, L. Jiang, F. Li, H. Lichtenberg-Frate, S. Haubrich, K. Willecke, S.A. Goldman, M. Nedergaard, Connexin 43 Enhances the Adhesivity and Mediates the Invasion of Malignant Glioma Cells, J. Neurosci., 22 (2002) 4302–4311.
[55] W. Zhang, C. Nwagwu, D.M. Le, V.W. Yong, H. Song, W.T. Couldwell, Increased invasive capacity of connexin43-overexpressing malignant glioma cells, J. Neurosurg., 99 (2003) 1039–1046.
[56] R. Oliveira, C. Christov, J.S. Guillamo, S. de Boüard, S. Palfi, L. Venance, M. Tardy, M. Peschanski, Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas, BMC Cell Biol., 6 (2005) 7.
[57] B. Tang, Z.-H. Peng, P.-W. Yu, G. Yu, F. Qian, D.-Z. Zeng, Y.-L. Zhao, Y. Shi, Y.-X. Hao, H.-X. Luo, Aberrant expression of Cx43 is associated with the peritoneal metastasis of gastric cancer and Cx43-mediated gap junction enhances gastric cancer cell diapedesis from peritoneal mesothelium, PLoS One, 8 (2013) e74527.
[58] A.S. Sun, H.C. Yeh, L.H. Wang, Y.P. Huang, H. Maeda, A. Pivazyan, C. Hsu, E.R. Lewis, H.W. Bruckner, T.M. Fasy, Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients, Nutr. Cancer, 39 (2001) 85–95.
[59] D.W. Bahler, J.G. Frelinger, L.W. Harwell, E.M. Lord, Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection, Proc. Natl. Acad. Sci. U. S. A., 84 (1987) 4562–4566.
[60] K.-T. Lin, J. Gong, C.-F. Li, T.-H. Jang, W.-L. Chen, H.-J. Chen, L.-H. Wang, Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence, Cancer Res., 72 (2012) 3000–3009.
[61] Y.-M. Yeh, C.-M. Chuang, K.-C. Chao, L.-H. Wang, MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α, Int. J. Cancer, 133 (2013) 867–878.
[62] M. Labelle, R.O. Hynes, The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination, Cancer Discov., 2 (2012) 1091–1099.
[63] D.R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, A.M. Chinnaiyan, ONCOMINE: a cancer microarray database and integrated data-mining platform, Neoplasia, 6 (2004) 1–6.
[64] I.J. Fidler, M.L. Kripke, The challenge of targeting metastasis, Cancer Metastasis Rev., 34 (2015) 635–641.
[65] H. Uramoto, F. Tanaka, Recurrence after surgery in patients with NSCLC, Transl Lung Cancer Res, 3 (2014) 242–249.
[66] B. Győrffy, P. Surowiak, J. Budczies, A. Lánczky, Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer, PLoS One, 8 (2013) e82241.
[67] J. Li, J. Lin, Y. Luo, M. Kuang, Y. Liu, Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer, PLoS One, 10 (2015) e0130640.
[68] M. Paesmans, Prognostic and predictive factors for lung cancer, Breathe, 9 (2012) 112–121.
[69] L.E. Coate, T. John, M.-S. Tsao, F.A. Shepherd, Molecular predictive and prognostic markers in non-small-cell lung cancer, Lancet Oncol., 10 (2009) 1001–1010.
[70] R.-Z. Liu, S. Li, E. Garcia, D.D. Glubrecht, H.Y. Poon, J.C. Easaw, R. Godbout, Association between cytoplasmic CRABP2, altered retinoic acid signaling, and poor prognosis in glioblastoma, Glia, 64 (2016) 963–976.
[71] S. Fischer-Huchzermeyer, A. Dombrowski, C. Hagel, V.F. Mautner, J. Schittenhelm, A. Harder, The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells, Am. J. Pathol., 187 (2017) 1623–1632.
[72] K.M.C. Mohammad Sultan, Retinoid Signaling in Cancer and Its Promise for Therapy, J Carcinog Mutagen, (2013).
[73] N. Mukherjee, P.J. Lager, M.B. Friedersdorf, M.A. Thompson, J.D. Keene, Coordinated posttranscriptional mRNA population dynamics during T-cell activation, Mol. Syst. Biol., 5 (2009) 288.
[74] Y.-C. Teng, C.-F. Lee, Y.-S. Li, Y.-R. Chen, P.-W. Hsiao, M.-Y. Chan, F.-M. Lin, H.-D. Huang, Y.-T. Chen, Y.-M. Jeng, C.-H. Hsu, Q. Yan, M.-D. Tsai, L.-J. Juan, Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis, Cancer Res., 73 (2013) 4711–4721.
[75] K.K. Ganguly, S. Pal, S. Moulik, A. Chatterjee, Integrins and metastasis, Cell Adh. Migr., 7 (2013) 251–261.
[76] F.J. Sulzmaier, C. Jean, D.D. Schlaepfer, FAK in cancer: mechanistic findings and clinical applications, Nat. Rev. Cancer, 14 (2014) 598–610.
[77] T. Miyazaki, H. Kato, M. Nakajima, M. Sohda, Y. Fukai, N. Masuda, R. Manda, M. Fukuchi, K. Tsukada, H. Kuwano, FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma, Br. J. Cancer, 89 (2003) 140–145.
[78] W. Guo, F.G. Giancotti, Integrin signalling during tumour progression, Nat. Rev. Mol. Cell Biol., 5 (2004) 816–826.
[79] R. Rosell, L. Crino, K. Danenberg, G. Scagliotti, G. Bepler, M. Taron, V. Alberola, M. Provencio, C. Camps, F. De Marinis, J.J. Sanchez, R. Peñas, Targeted therapy in combination with gemcitabine in non-small cell lung cancer, Semin. Oncol., 30 (2003) 19–25.
[80] Y. Lin, X. Wang, H. Jin, EGFR-TKI resistance in NSCLC patients: mechanisms and strategies, Am. J. Cancer Res., 4 (2014) 411–435.
[81] B. Wills, A.F. Cardona, L. Rojas, A. Ruiz-Patiño, O. Arrieta, N. Reguart, H. Carranza, C. Vargas, J. Otero, L. Corrales, C. Martín, M. Cuello, L.E. Pino, C. Rolfo, R. Rosell, Z.L. Zatarain-Barrón, Latin-American Consortium for the Investigation of Lung Cancer (CLICaP), Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab, Anticancer Res., 37 (2017) 6429–6436.
[82] Y. Xu, M.A. Villalona-Calero, Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity, Ann. Oncol., 13 (2002) 1841–1851.
[83] W.-A. Wang, J. Groenendyk, M. Michalak, Endoplasmic reticulum stress associated responses in cancer, Biochim. Biophys. Acta, 1843 (2014) 2143–2149.
[84] A.S. Lee, The glucose-regulated proteins: stress induction and clinical applications, Trends Biochem. Sci., 26 (2001) 504–510.
[85] Y. Xu, Z. Chen, G. Zhang, Y. Xi, R. Sun, X. Wang, W. Wang, F. Chai, X. Li, HSP90B1 overexpression predicts poor prognosis in NSCLC patients, Tumour Biol., 37 (2016) 14321–14328.
[86] B.-Y. Jin, G.-H. Fu, X. Jiang, H. Pan, D.-K. Zhou, X.-Y. Wei, L. Zhou, L. Chung, S.-S. Zheng, CRABP2 and FABP5 identified by 2D DIGE profiling are upregulated in human bladder cancer, Chin. Med. J. , 126 (2013) 3787–3789.
[87] A. Gupta, P. Kessler, J. Rawwas, B.R.G. Williams, Regulation of CRABP-II expression by MycN in Wilms tumor, Exp. Cell Res., 314 (2008) 3663–3668.
[88] A. Gupta, B.R.G. Williams, S.M. Hanash, J. Rawwas, Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma, Cancer Res., 66 (2006) 8100–8108.
[89] W. Xiao, H. Hong, A. Awadallah, S. Yu, L. Zhou, W. Xin, CRABP-II is a highly sensitive and specific diagnostic molecular marker for pancreatic ductal adenocarcinoma in distinguishing from benign pancreatic conditions, Hum. Pathol., 45 (2014) 1177–1183.
[90] A. Toyama, A. Suzuki, T. Shimada, C. Aoki, Y. Aoki, Y. Umino, Y. Nakamura, D. Aoki, T.-A. Sato, Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers, Cancer Sci., 103 (2012) 747–755.
[91] A.P. Percicote, G.L. Mardegan, E.S. Gugelmim, S.O. Ioshii, A.P. Kuczynski, S. Nagashima, L. de Noronha, Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas, Diagn. Pathol., 13 (2018) 9.
[92] A.H. Cory, T.C. Owen, J.A. Barltrop, J.G. Cory, Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture, Cancer Commun., 3 (1991) 207–212.
[93] D.L. Crowe, R. Kim, R.A.S. Chandraratna, Retinoic acid differentially regulates cancer cell proliferation via dose-dependent modulation of the mitogen-activated protein kinase pathway, Mol. Cancer Res., 1 (2003) 532–540.
[94] T.T. Schug, D.C. Berry, N.S. Shaw, S.N. Travis, N. Noy, Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors, Cell, 129 (2007) 723–733.
[95] R.M. Connolly, N.K. Nguyen, S. Sukumar, Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment, Clin. Cancer Res., 19 (2013) 1651–1659.
[96] J.L. Napoli, Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: Effects on retinoid metabolism, function and related diseases, Pharmacol. Ther., 173 (2017) 19–33.
[97] B. Weber, H. Hager, B.S. Sorensen, T. McCulloch, A. Mellemgaard, A.A. Khalil, E. Nexo, P. Meldgaard, EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer, Lung Cancer, 83 (2014) 224–230.
[98] H.A. Yu, M.E. Arcila, M.D. Hellmann, M.G. Kris, M. Ladanyi, G.J. Riely, Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing, Ann. Oncol., 25 (2014) 423–428.
[99] C. Willmore-Payne, J.A. Holden, C.T. Wittwer, L.J. Layfield, The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer, J. Biomol. Tech., 19 (2008) 217–224.
[100] M.L. Sos, M. Koker, B.A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J.M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel, L. Girard, M. Peyton, A.F. Gazdar, J.D. Minna, L.A. Garraway, H. Kashkar, W. Pao, et al., PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR, Cancer Res., 69 (2009) 3256–3261.
[101] M. Prieto-Vila, R.-U. Takahashi, W. Usuba, I. Kohama, T. Ochiya, Drug Resistance Driven by Cancer Stem Cells and Their Niche, Int. J. Mol. Sci., 18 (2017).
[102] M. Ghosh, H.L. Aguila, J. Michaud, Y. Ai, M.-T. Wu, A. Hemmes, A. Ristimaki, C. Guo, H. Furneaux, T. Hla, Essential role of the RNA-binding protein HuR in progenitor cell survival in mice, J. Clin. Invest., 119 (2009) 3530–3543.
[103] M. Singh, A.R. Martinez, S. Govindaraju, B.S. Lee, HuR inhibits apoptosis by amplifying Akt signaling through a positive feedback loop, J. Cell. Physiol., 228 (2013) 182–189.
[104] X. Guan, Cancer metastases: challenges and opportunities, Acta Pharm Sin B, 5 (2015) 402–418.
[105] G. Spagnol, A.J. Trease, L. Zheng, M. Gutierrez, I. Basu, C. Sarmiento, G. Moore, M. Cervantes, P.L. Sorgen, Connexin43 Carboxyl-Terminal Domain Directly Interacts with β-Catenin, Int. J. Mol. Sci., 19 (2018).
[106] Z. Ai, A. Fischer, D.C. Spray, A.M. Brown, G.I. Fishman, Wnt-1 regulation of connexin43 in cardiac myocytes, J. Clin. Invest., 105 (2000) 161–171.
[107] R.P. Huang, M.Z. Hossain, R. Huang, J. Gano, Y. Fan, A.L. Boynton, Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells, Int. J. Cancer, 92 (2001) 130–138.
[108] H.-T. Xu, Q.-C. Li, Y.-X. Zhang, Y. Zhao, Y. Liu, Z.-Q. Yang, E.-H. Wang, Connexin 43 recruits E-cadherin expression and inhibits the malignant behaviour of lung cancer cells, Folia Histochem. Cytobiol., 46 (2008) 315–321.
[109] K.C. Alaga, M. Crawford, L. Dagnino, D.W. Laird, Aberrant Cx43 Expression and Mislocalization in Metastatic Human Melanomas, J. Cancer, 8 (2017) 1123–1128.
[110] L. Kańczuga-Koda, M. Sulkowska, M. Koda, J. Reszeć, W. Famulski, M. Baltaziak, S. Sulkowski, Expression of connexin 43 in breast cancer in comparison with mammary dysplasia and the normal mammary gland, Folia Morphol. , 62 (2003) 439–442.
[111] Q.-L. Liang, B.-R. Wang, G.-Q. Chen, G.-H. Li, Y.-Y. Xu, Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters, Med. Oncol., 27 (2010) 1164–1170.
[112] Zhang Y., Xu H., Wang E., [Expressions of connexin 43 and E-cadherin and their correlation in non-small cell lung cancer], Zhongguo Fei Ai Za Zhi, 8 (2005) 103–106.
[113] Sun W.-H., Liu H.-M., Li Y.-J., Ji X.-R., Liang D.-P., [A study of the relationship between the expression of connexin43, E-cadherin and biological behaviors of human laryngeal cancer], Zhonghua Er Bi Yan Hou Ke Za Zhi, 39 (2004) 293–297.
[114] L. Puzzo, R. Caltabiano, R. Parenti, S. Trapasso, E. Allegra, Connexin 43 (Cx43) Expression in Laryngeal Squamous Cell Carcinomas: Preliminary Data on Its Possible Prognostic Role, Head Neck Pathol., 10 (2016) 292–297.
[115] J.W. Smyth, T.-T. Hong, D. Gao, J.M. Vogan, B.C. Jensen, T.S. Fong, P.C. Simpson, D.Y.R. Stainier, N.C. Chi, R.M. Shaw, Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium, J. Clin. Invest., 120 (2010) 266–279.
[116] J.E. Klaunig, L.M. Kamendulis, The role of oxidative stress in carcinogenesis, Annu. Rev. Pharmacol. Toxicol., 44 (2004) 239–267.
[117] V. Sosa, T. Moliné, R. Somoza, R. Paciucci, H. Kondoh, M.E. LLeonart, Oxidative stress and cancer: an overview, Ageing Res. Rev., 12 (2013) 376–390.
[118] J. Ming, Y. Zhou, J. Du, S. Fan, B. Pan, Y. Wang, L. Fan, J. Jiang, miR-381 suppresses C/EBPα-dependent Cx43 expression in breast cancer cells, Biosci. Rep., 35 (2015).
[119] Z.-J. Lin, J. Ming, L. Yang, J.-Z. Du, N. Wang, H.-J. Luo, Mechanism of Regulatory Effect of MicroRNA-206 on Connexin 43 in Distant Metastasis of Breast Cancer, Chin. Med. J. , 129 (2016) 424–434.
[120] J. Ming, Y. Zhou, J. Du, S. Fan, B. Pan, Y. Wang, L. Fan, J. Jiang, Identification of miR-200a as a novel suppressor of connexin 43 in breast cancer cells, Biosci. Rep., 35 (2015).
[121] F. Gava, L. Rigal, O. Mondesert, E. Pesce, B. Ducommun, V. Lobjois, Gap junctions contribute to anchorage-independent clustering of breast cancer cells, BMC Cancer, 18 (2018) 221.
[122] L.A.B. Elias, D.D. Wang, A.R. Kriegstein, Gap junction adhesion is necessary for radial migration in the neocortex, Nature, 448 (2007) 901–907.
[123] M.E. el-Sabban, B.U. Pauli, Cytoplasmic dye transfer between metastatic tumor cells and vascular endothelium, J. Cell Biol., 115 (1991) 1375–1382.
[124] A. Zhang, M. Hitomi, N. Bar-Shain, Z. Dalimov, L. Ellis, K.K. Velpula, G.C. Fraizer, R.G. Gourdie, J.D. Lathia, Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration, Oncotarget, 6 (2015) 11640–11651.
[125] J. Behrens, P. Kameritsch, S. Wallner, U. Pohl, K. Pogoda, The carboxyl tail of Cx43 augments p38 mediated cell migration in a gap junction-independent manner, Eur. J. Cell Biol., 89 (2010) 828–838.
[126] S. Ghosh, A. Kumar, R.P. Tripathi, S. Chandna, Connexin-43 regulates p38-mediated cell migration and invasion induced selectively in tumour cells by low doses of γ-radiation in an ERK-1/2-independent manner, Carcinogenesis, 35 (2014) 383–395.
[127] A.J. Siller-Jackson, S. Burra, S. Gu, X. Xia, L.F. Bonewald, E. Sprague, J.X. Jiang, Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading, J. Biol. Chem., 283 (2008) 26374–26382.
[128] G.M. Yusubalieva, V.P. Baklaushev, O.I. Gurina, Y.A. Zorkina, I.L. Gubskii, G.L. Kobyakov, A.V. Golanov, S.A. Goryainov, G.E. Gorlachev, A.N. Konovalov, A.A. Potapov, V.P. Chekhonin, Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy, Bull. Exp. Biol. Med., 157 (2014) 510–515.
[129] L. Franco, E. Zocchi, C. Usai, L. Guida, S. Bruzzone, A. Costa, A. De Flora, Paracrine roles of NAD+ and cyclic ADP-ribose in increasing intracellular calcium and enhancing cell proliferation of 3T3 fibroblasts, J. Biol. Chem., 276 (2001) 21642–21648.
[130] J.M. Rhett, E.S. Yeh, The Potential for Connexin Hemichannels to Drive Breast Cancer Progression through Regulation of the Inflammatory Response, Int. J. Mol. Sci., 19 (2018).
[131] K.A. Schalper, D. Carvajal-Hausdorf, M.P. Oyarzo, Possible role of hemichannels in cancer, Front. Physiol., 5 (2014) 237.
[132] Y. Fu, Z.-M. Shao, Q.-Z. He, B.-Q. Jiang, Y. Wu, Z.-G. Zhuang, Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43, Eur. Rev. Med. Pharmacol. Sci., 19 (2015) 2091–2104.
[133] Z. Wang, D.-Z. Wang, G.C.T. Pipes, E.N. Olson, Myocardin is a master regulator of smooth muscle gene expression, Proc. Natl. Acad. Sci. U. S. A., 100 (2003) 7129–7134.
[134] H. Li, Y. Xiang, L.-J. Fan, X.-Y. Zhang, J.-P. Li, C.-X. Yu, L.-Y. Bao, D.-S. Cao, W.-B. Xing, X.-H. Liao, T.-C. Zhang, Myocardin inhibited the gap protein connexin 43 via promoted miR-206 to regulate vascular smooth muscle cell phenotypic switch, Gene, 616 (2017) 22–30.
[135] B. Davidson, V.M. Abeler, M. Førsund, A. Holth, Y. Yang, Y. Kobayashi, L. Chen, G.B. Kristensen, I.-M. Shih, T.-L. Wang, Gene expression signatures of primary and metastatic uterine leiomyosarcoma, Hum. Pathol., 45 (2014) 691–700.
[136] D. Ryszawy, M. Sarna, M. Rak, K. Szpak, S. Kędracka-Krok, M. Michalik, M. Siedlar, E. Zuba-Surma, K. Burda, W. Korohoda, Z. Madeja, J. Czyż, Functional links between Snail-1 and Cx43 account for the recruitment of Cx43-positive cells into the invasive front of prostate cancer, Carcinogenesis, 35 (2014) 1920–1930.
[137] Y. Wang, J. Liu, X. Ying, P.C. Lin, B.P. Zhou, Twist-mediated Epithelial-mesenchymal Transition Promotes Breast Tumor Cell Invasion via Inhibition of Hippo Pathway, Sci. Rep., 6 (2016) 24606.
[138] Y. Naoi, Y. Miyoshi, T. Taguchi, S.J. Kim, T. Arai, Y. Tamaki, S. Noguchi, Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer, Breast Cancer Res. Treat., 106 (2007) 11–17.
[139] K. Ezumi, H. Yamamoto, K. Murata, M. Higashiyama, B. Damdinsuren, Y. Nakamura, N. Kyo, J. Okami, C.Y. Ngan, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, H. Nojima, M. Monden, Aberrant Expression of Connexin 26 Is Associated with Lung Metastasis of Colorectal Cancer, Clin. Cancer Res., 14 (2008) 677–684.
[140] Y. Naoi, Y. Miyoshi, T. Taguchi, S.J. Kim, T. Arai, N. Maruyama, Y. Tamaki, S. Noguchi, Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers, Cancer Lett., 262 (2008) 248–256.
[141] T. Inose, H. Kato, H. Kimura, A. Faried, N. Tanaka, M. Sakai, A. Sano, M. Sohda, M. Nakajima, Y. Fukai, T. Miyazaki, N. Masuda, M. Fukuchi, H. Kuwano, Correlation between connexin 26 expression and poor prognosis of esophageal squamous cell carcinoma, Ann. Surg. Oncol., 16 (2009) 1704–1710.
[142] J. Yang, G. Qin, M. Luo, J. Chen, Q. Zhang, L. Li, L. Pan, S. Qin, Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT, Cell Death Dis., 6 (2015) e1829.
[143] A. Ito, F. Katoh, T.R. Kataoka, M. Okada, N. Tsubota, H. Asada, K. Yoshikawa, S. Maeda, Y. Kitamura, H. Yamasaki, H. Nojima, A role for heterologous gap junctions between melanoma and endothelial cells in metastasis, J. Clin. Invest., 105 (2000) 1189–1197.
[144] A. Duflot-Dancer, M. Mesnil, H. Yamasaki, Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes, Oncogene, 15 (1997) 2151–2158.
[145] L. Kanczuga-Koda, M. Sulkowska, M. Koda, R. Rutkowski, S. Sulkowski, Increased expression of gap junction protein--connexin 32 in lymph node metastases of human ductal breast cancer, Folia Histochem. Cytobiol., 45 Suppl 1 (2007) S175–80.
[146] V. Krutovskikh, G. Mazzoleni, N. Mironov, Y. Omori, A.M. Aguelon, M. Mesnil, F. Berger, C. Partensky, H. Yamasaki, Altered homologous and heterologous gap-junctional intercellular communication in primary human liver tumors associated with aberrant protein localization but not gene mutation of connexin 32, Int. J. Cancer, 56 (1994) 87–94.
[147] Q. Li, Y. Omori, Y. Nishikawa, T. Yoshioka, Y. Yamamoto, K. Enomoto, Cytoplasmic accumulation of connexin32 protein enhances motility and metastatic ability of human hepatoma cells in vitro and in vivo, Int. J. Cancer, 121 (2007) 536–546.
[148] J. Yang, B. Liu, Q. Wang, D. Yuan, X. Hong, Y. Yang, L. Tao, Connexin 32 and its derived homotypic gap junctional intercellular communication inhibit the migration and invasion of transfected HeLa cells via enhancement of intercellular adhesion, Mol. Med. Rep., 4 (2011) 971–979.
[149] Y. Yang, S.-K. Qin, Q. Wu, Z.-S. Wang, R.-S. Zheng, X.-H. Tong, H. Liu, L. Tao, X.-D. He, Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition, Oncol. Rep., 31 (2014) 540–550.
[150] E. Fujimoto, H. Sato, S. Shirai, Y. Nagashima, K. Fukumoto, H. Hagiwara, E. Negishi, K. Ueno, Y. Omori, H. Yamasaki, K. Hagiwara, T. Yano, Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line, Oncogene, 24 (2005) 3684–3690.
[151] H. Sato, H. Hagiwara, H. Senba, K. Fukumoto, Y. Nagashima, H. Yamasaki, K. Ueno, T. Yano, The inhibitory effect of connexin 32 gene on metastasis in renal cell carcinoma, Mol. Carcinog., 47 (2008) 403–409.
[152] H. Hagiwara, H. Sato, S. Shirai, S. Kobayashi, K. Fukumoto, T. Ishida, T. Seki, T. Ariga, T. Yano, Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells, Life Sci., 78 (2006) 2249–2254.
[153] Y. Yang, N. Zhang, J. Zhu, X.-T. Hong, H. Liu, Y.-R. Ou, F. Su, R. Wang, Y.-M. Li, Q. Wu, Downregulated connexin32 promotes EMT through the Wnt/β-catenin pathway by targeting Snail expression in hepatocellular carcinoma, Int. J. Oncol., 50 (2017) 1977–1988.
[154] B. Zhao, W. Zhao, Y. Wang, Y. Xu, J. Xu, K. Tang, S. Zhang, Z. Yin, Q. Wu, X. Wang, Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways, Oncotarget, 6 (2015) 10116–10133.
[155] D. Zhang, C. Chen, Y. Li, X. Fu, Y. Xie, Y. Li, Y. Huang, Cx311 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis, J. Cell. Mol. Med., 16 (2012) 1047–1059.
[156] L. Xu, S.-W. Chen, X.-Y. Qi, X.-X. Li, Y.-B. Sun, Ginsenoside improves papillary thyroid cancer cell malignancies partially through upregulating connexin 31, Kaohsiung J. Med. Sci., 34 (2018) 313–320.
[157] Jin J., Li C., You J., Zhang B., [miR-610 suppresses lung cancer cell proliferation and invasion by targeting GJA3], Zhonghua Zhong Liu Za Zhi, 36 (2014) 405–411.
[158] Y.-P. Lin, J.-I. Wu, C.-W. Tseng, H.-J. Chen, L.-H. Wang, Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation, Oncogene, (2018).
[159] J. Radić, B. Krušlin, M. Šamija, M. Ulamec, M. Milošević, M. Jazvić, I. Šamija, J.J. Grah, A. Bolanča, Z. Kusić, Connexin 43 Expression in Primary Colorectal Carcinomas in Patients with Stage III and IV Disease, Anticancer Res., 36 (2016) 2189–2196.
[160] X. Zhang, Y. Sun, Z. Wang, Z. Huang, B. Li, J. Fu, Up-regulation of connexin-43 expression in bone marrow mesenchymal stem cells plays a crucial role in adhesion and migration of multiple myeloma cells, Leuk. Lymphoma, 56 (2015) 211–218.
[161] N.K. Haass, D. Ripperger, E. Wladykowski, P. Dawson, P.A. Gimotty, C. Blome, F. Fischer, P. Schmage, I. Moll, J.M. Brandner, Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment, Histochem. Cell Biol., 133 (2010) 113–124.
[162] W.C. Sin, Q. Aftab, J.F. Bechberger, J.H. Leung, H. Chen, C.C. Naus, Astrocytes promote glioma invasion via the gap junction protein connexin43, Oncogene, 35 (2016) 1504–1516.
[163] C. Beck, S. Cayeux, S.D. Lupton, B. Dörken, T. Blankenstein, The thymidine kinase/ganciclovir-mediated “suicide” effect is variable in different tumor cells, Hum. Gene Ther., 6 (1995) 1525–1530.
[164] T. Jimenez, W.P. Fox, C.C.G. Naus, J. Galipeau, D.J. Belliveau, Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy, Cell Commun. Adhes., 13 (2006) 79–92.
[165] S. Matono, T. Tanaka, S. Sueyoshi, H. Yamana, H. Fujita, K. Shirouzu, Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer, Int. J. Oncol., 23 (2003) 1309–1315.
[166] K. Rtibi, D. Grami, S. Selmi, M. Amri, H. Sebai, L. Marzouki, Vinblastine, an anticancer drug, causes constipation and oxidative stress as well as others disruptions in intestinal tract in rat, Toxicol Rep, 4 (2017) 221–225.
[167] P.H.M. De Mulder, C.M.L. van Herpen, P.A.F. Mulders, Current treatment of renal cell carcinoma, Ann. Oncol., 15 Suppl 4 (2004) iv319–28.
[168] H. Sato, H. Senba, N. Virgona, K. Fukumoto, T. Ishida, H. Hagiwara, E. Negishi, K. Ueno, H. Yamasaki, T. Yano, Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells, Mol. Carcinog., 46 (2007) 215–224.
[169] H. Sato, K. Fukumoto, S. Hada, H. Hagiwara, E. Fujimoto, E. Negishi, K. Ueno, T. Yano, Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells, Cancer Chemother. Pharmacol., 60 (2007) 449–457.
[170] M.C. Piccirillo, G. Daniele, M. Di Maio, J. Bryce, G. De Feo, A. Del Giudice, F. Perrone, A. Morabito, Vinorelbine for non-small cell lung cancer, Expert Opin. Drug Saf., 9 (2010) 493–510.
[171] R.P. Huang, Y. Fan, M.Z. Hossain, A. Peng, Z.L. Zeng, A.L. Boynton, Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43), Cancer Res., 58 (1998) 5089–5096.
[172] M. Uzu, H. Sato, R. Yamada, T. Kashiba, Y. Shibata, K. Yamaura, K. Ueno, Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells, J. Pharmacol. Sci., 128 (2015) 17–26.
[173] D.W. Laird, Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation, Biochim. Biophys. Acta, 1711 (2005) 172–182.
[174] J.L. Solan, P.D. Lampe, Connexin phosphorylation as a regulatory event linked to gap junction channel assembly, Biochim. Biophys. Acta, 1711 (2005) 154–163.
[175] Y. Guo, C. Martinez-Williams, D.E. Rannels, Gap junction-microtubule associations in rat alveolar epithelial cells, Am. J. Physiol. Lung Cell. Mol. Physiol., 285 (2003) L1213–21.
[176] R.G. Johnson, R.A. Meyer, X.-R. Li, D.M. Preus, L. Tan, H. Grunenwald, A.F. Paulson, D.W. Laird, J.D. Sheridan, Gap junctions assemble in the presence of cytoskeletal inhibitors, but enhanced assembly requires microtubules, Exp. Cell Res., 275 (2002) 67–80.
[177] P.E. Martin, G. Blundell, S. Ahmad, R.J. Errington, W.H. Evans, Multiple pathways in the trafficking and assembly of connexin 26, 32 and 43 into gap junction intercellular communication channels, J. Cell Sci., 114 (2001) 3845–3855.
[178] B.N.G. Giepmans, Gap junctions and connexin-interacting proteins, Cardiovasc. Res., 62 (2004) 233–245.
[179] T. Kojima, N. Sawada, H. Chiba, Y. Kokai, M. Yamamoto, M. Urban, G.H. Lee, E.L. Hertzberg, Y. Mochizuki, D.C. Spray, Induction of tight junctions in human connexin 32 (hCx32)-transfected mouse hepatocytes: connexin 32 interacts with occludin, Biochem. Biophys. Res. Commun., 266 (1999) 222–229.
[180] T. Kojima, Y. Kokai, H. Chiba, M. Yamamoto, Y. Mochizuki, N. Sawada, Cx32 but not Cx26 is associated with tight junctions in primary cultures of rat hepatocytes, Exp. Cell Res., 263 (2001) 193–201.
[181] T.A. Martin, W.G. Jiang, Loss of tight junction barrier function and its role in cancer metastasis, Biochim. Biophys. Acta, 1788 (2009) 872–891.
[182] A. Ito, N. Morita, D. Miura, Y.-I. Koma, T.R. Kataoka, H. Yamasaki, Y. Kitamura, Y. Kita, H. Nojima, A derivative of oleamide potently inhibits the spontaneous metastasis of mouse melanoma BL6 cells, Carcinogenesis, 25 (2004) 2015–2022.
[183] D. Miura, Y. Kida, H. Nojima, Camellia oil and its distillate fractions effectively inhibit the spontaneous metastasis of mouse melanoma BL6 cells, FEBS Lett., 581 (2007) 2541–2548.
[184] S. Ferrati, A.K. Gadok, A.D. Brunaugh, C. Zhao, L.A. Heersema, H.D.C. Smyth, J.C. Stachowiak, Connexin membrane materials as potent inhibitors of breast cancer cell migration, J. R. Soc. Interface, 14 (2017).
[185] G. Charras, E. Paluch, Blebs lead the way: how to migrate without lamellipodia, Nat. Rev. Mol. Cell Biol., 9 (2008) 730.
[186] P.E.M. Martin, W.H. Evans, Incorporation of connexins into plasma membranes and gap junctions, Cardiovasc. Res., 62 (2004) 378–387.
[187] A.W. Hunter, R.J. Barker, C. Zhu, R.G. Gourdie, Zonula occludens-1 alters connexin43 gap junction size and organization by influencing channel accretion, Mol. Biol. Cell, 16 (2005) 5686–5698.
[188] J.M. Rhett, J. Jourdan, R.G. Gourdie, Connexin 43 connexon to gap junction transition is regulated by zonula occludens-1, Mol. Biol. Cell, 22 (2011) 1516–1528.
[189] G.S. Ghatnekar, C.L. Grek, D.G. Armstrong, S.C. Desai, R.G. Gourdie, The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial, J. Invest. Dermatol., 135 (2015) 289–298.
[190] C.L. Grek, J.M. Rhett, J.S. Bruce, M.A. Abt, G.S. Ghatnekar, E.S. Yeh, Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1, BMC Cancer, 15 (2015) 296.
[191] V.C. Jordan, The role of tamoxifen in the treatment and prevention of breast cancer, Curr. Probl. Cancer, 16 (1992) 129–176.
[192] D. Bilancia, G. Rosati, A. Dinota, D. Germano, R. Romano, L. Manzione, Lapatinib in breast cancer, Ann. Oncol., 18 Suppl 6 (2007) vi26–30.
[193] M. Jaraíz-Rodríguez, M.D. Tabernero, M. González-Tablas, A. Otero, A. Orfao, J.M. Medina, A. Tabernero, A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK, Stem Cell Reports, 9 (2017) 451–463.
[194] B.W. Calder, J. Matthew Rhett, H. Bainbridge, S.A. Fann, R.G. Gourdie, M.J. Yost, Inhibition of connexin 43 hemichannel-mediated ATP release attenuates early inflammation during the foreign body response, Tissue Eng. Part A, 21 (2015) 1752–1762.
[195] J.M. Rhett, B.W. Calder, S.A. Fann, H. Bainbridge, R.G. Gourdie, M.J. Yost, Mechanism of action of the anti-inflammatory connexin43 mimetic peptide JM2, Am. J. Physiol. Cell Physiol., 313 (2017) C314–C326.
[196] S.N. Shishido, A. Delahaye, A. Beck, T.A. Nguyen, The anticancer effect of PQ1 in the MMTV-PyVT mouse model, Int. J. Cancer, 134 (2014) 1474–1483.
[197] C.-F. Tsai, Y.-K. Cheng, D.-Y. Lu, S.-L. Wang, C.-N. Chang, P.-C. Chang, W.-L. Yeh, Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers, Toxicol. Appl. Pharmacol., 338 (2018) 182–190.
[198] T.N. Zamay, G.S. Zamay, O.S. Kolovskaya, R.A. Zukov, M.M. Petrova, A. Gargaun, M.V. Berezovski, A.S. Kichkailo, Current and Prospective Protein Biomarkers of Lung Cancer, Cancers , 9 (2017).
[199] N. Okabe, J. Ezaki, T. Yamaura, S. Muto, J. Osugi, H. Tamura, J.-I. Imai, E. Ito, Y. Yanagisawa, R. Honma, M. Gotoh, S. Watanabe, S. Waguri, H. Suzuki, FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma, Int. J. Oncol., 46 (2015) 999–1006.
[200] M. Cristofanilli, G.T. Budd, M.J. Ellis, A. Stopeck, J. Matera, M.C. Miller, J.M. Reuben, G.V. Doyle, W.J. Allard, L.W.M.M. Terstappen, D.F. Hayes, Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N. Engl. J. Med., 351 (2004) 781–791.
[201] M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å. Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani, C.A.-K. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober, T. Alm, et al., Proteomics Tissue-based map of the human proteome, Science, 347 (2015) 1260419.
[202] D.J. Kim, W.J. Kim, M. Lim, Y. Hong, S.-J. Lee, S.-H. Hong, J. Heo, H.-Y. Lee, S.-S. Han, Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer, J. Korean Med. Sci., 33 (2018) e178.
[203] I. López de Silanes, M. Zhan, A. Lal, X. Yang, M. Gorospe, Identification of a target RNA motif for RNA-binding protein HuR, Proc. Natl. Acad. Sci. U. S. A., 101 (2004) 2987–2992.
[204] W. Zhang, A.C. Vreeland, N. Noy, RNA-binding protein HuR regulates nuclear import of protein, J. Cell Sci., 129 (2016) 4025–4033.
[205] F. Milletti, Cell-penetrating peptides: classes, origin, and current landscape, Drug Discov. Today, 17 (2012) 850–860.
[206] G. Hardavella, R. George, T. Sethi, Lung cancer stem cells-characteristics, phenotype, Transl Lung Cancer Res, 5 (2016) 272–279. |